Cornelis Wesdorp
Known title: Pres & CEO, Digital HealthCIK: 0002037343
Associated companies
Transaction History
| RDNT | ▼ Sell | Open Market | 4,750 | $276K | 6/16/2026 | View on chart |
| RDNT | ▲ Buy | Grant | 20,330 | $0 | 3/3/2026 | View on chart |
| RDNT | ▼ Sell | Open Market | 500 | $36K | 9/11/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 500 | $36K | 9/9/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 1,500 | $100K | 8/19/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 1,000 | $51K | 3/7/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 2,000 | $102K | 3/6/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 2,000 | $105K | 3/5/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 60,995 | $0 | 10/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.